Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

<p dir="ltr">Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked...

Full description

Saved in:
Bibliographic Details
Main Author: Mona O. Mohsen (4056964) (author)
Other Authors: Monique Vogel (405685) (author), Carsten Riether (509910) (author), Julius Muller (4098391) (author), Silvia Salatino (184189) (author), Nicola Ternette (68528) (author), Ariane C. Gomes (7116413) (author), Gustavo Cabral-Miranda (6641204) (author), Aadil El-Turabi (4348864) (author), Christiane Ruedl (211913) (author), Thomas M. Kundig (18131773) (author), Said Dermime (79420) (author), Alexander Knuth (11104) (author), Daniel E. Speiser (8262588) (author), Martin F. Bachmann (7116422) (author)
Published: 2019
Subjects:
Biomedical and clinical sciences
Immunology
virus-like particles
vaccine
personalized
melanoma
neoantigen
mutated
germline
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items